Delivery Order SPE2DB20D3101-SPE2DB22FJ9F9
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OFLOXACIN 0.3% EAR DROPS 5ML. The $5,469.25 firm fixed-price delivery order has an ultimate completion date of January 17, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,594.16 firm-fixed-price delivery order is for OFLOXACIN 0.3% EAR DROPS 10ML, with a completion date of September 13, 2022. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award is for the delivery of OFLOXACIN 0.3% EAR DROPS 10ML to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,945.69, is a Firm Fixed Price Delivery Order with an ultimate completion date of August 16, 2021. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc.,...
- This federal contract award, valued at $8,973.24, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is a Delivery Order for the supply of 4558473440 - OFLOXACIN 0.3% EAR DROPS 5ML, with an ultimate completion date of September 16, 2022. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of OFLOXACIN 0.3% EAR DROPS 10ML, a pharmaceutical product, with a ceiling value of $3,486.18. The contract was awarded on September 27, 2022, with a completion date of September 28, 2022, and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider...
- This federal contract award to Amerisourcebergen Drug Corp is for the delivery of OFLOXACIN 0.3% EAR DROPS 10ML, with a ceiling value of $1,933.30. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical...
- This federal contract award, SPE2DB20D3103|SPE2DB23FN3E3, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of OFLOXACIN 0.3% EAR DROPS 5ML. The $2,976.65 firm fixed-price delivery order has a completion date of May 9, 2023 and is not designated as a set-aside. Amerisourcebergen, a for-profit organization registered in the System for Award Management (SAM.gov), has an extensive history of federal contract...
- The federal contract award is for the delivery of Ofloxacin 0.3% ear drops, 10ml, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a pharmaceutical distribution company that serves as a key supplier of medical products to federal government agencies, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The contract has a ceiling value of $3,411.61 and is a delivery order under an Indefinite Delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,135.75 contract is for the supply of OFLOXACIN 0.3% EAR DROPS 5ML, a pharmaceutical product, with a completion date of July 26, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award is for the delivery of Ofloxacin 0.3% ear drops in 10 mL bottles to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $4,157.34 and a period of performance ending on December 28, 2021. The contract was awarded on December 27, 2021 and does not have a set-aside...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB22FJ9F9Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,089.42 firm fixed price delivery order is for the supply of OFLOXACIN 0.3% EAR DROPS 10ML. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical. This single-award IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense globally. The contract has no set-aside designation, indicating open competition. Amerisourcebergen, a subsidiary of parent company Cencora, Inc., is a critical supplier of essential medications, medical devices, and other healthcare commodities to federal government agencies, particularly the military and veterans' healthcare systems. This contract award demonstrates the company's capacity to efficiently fulfill the DLA's pharmaceutical and medical supply needs through a streamlined contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 5/25/22 |